| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| HIV-1 | 17 | 2019 | 3365 | 0.89 | Why? |
| Hepatitis C, Chronic | 10 | 2019 | 973 | 0.82 | Why? |
| Hepacivirus | 10 | 2018 | 1509 | 0.74 | Why? |
| Drug Resistance, Viral | 8 | 2019 | 1083 | 0.63 | Why? |
| Biotechnology | 1 | 2017 | 444 | 0.53 | Why? |
| Serologic Tests | 3 | 2021 | 4359 | 0.46 | Why? |
| Filtration | 1 | 2017 | 820 | 0.44 | Why? |
| Genotype | 14 | 2019 | 4697 | 0.43 | Why? |
| RNA, Viral | 11 | 2021 | 32276 | 0.43 | Why? |
| HIV Infections | 15 | 2019 | 11620 | 0.41 | Why? |
| Hepatitis C | 6 | 2018 | 1514 | 0.40 | Why? |
| Metal Nanoparticles | 1 | 2017 | 771 | 0.40 | Why? |
| HIV Reverse Transcriptase | 3 | 2018 | 104 | 0.40 | Why? |
| HIV Integrase | 2 | 2019 | 67 | 0.35 | Why? |
| Anti-HIV Agents | 7 | 2019 | 2209 | 0.35 | Why? |
| Viral Load | 14 | 2021 | 15850 | 0.35 | Why? |
| DNA, Viral | 7 | 2018 | 2521 | 0.33 | Why? |
| Anti-Retroviral Agents | 4 | 2019 | 1099 | 0.32 | Why? |
| Hepatitis B virus | 3 | 2018 | 882 | 0.31 | Why? |
| HIV Integrase Inhibitors | 2 | 2018 | 173 | 0.31 | Why? |
| Real-Time Polymerase Chain Reaction | 3 | 2021 | 11367 | 0.27 | Why? |
| Carcinoma, Hepatocellular | 3 | 2018 | 1222 | 0.25 | Why? |
| Nasopharynx | 3 | 2021 | 10224 | 0.25 | Why? |
| Cytomegalovirus | 2 | 2018 | 600 | 0.24 | Why? |
| Antiviral Agents | 16 | 2020 | 41703 | 0.24 | Why? |
| Hepatitis B, Chronic | 3 | 2018 | 616 | 0.24 | Why? |
| Viremia | 2 | 2021 | 1020 | 0.23 | Why? |
| Respiratory Syncytial Viruses | 1 | 2006 | 612 | 0.23 | Why? |
| Respiratory Tract Infections | 2 | 2017 | 6817 | 0.23 | Why? |
| Liver Neoplasms | 3 | 2018 | 1666 | 0.22 | Why? |
| Proof of Concept Study | 2 | 2021 | 696 | 0.22 | Why? |
| Retreatment | 2 | 2017 | 186 | 0.21 | Why? |
| Tuberculosis, Lymph Node | 1 | 2019 | 27 | 0.21 | Why? |
| HIV Protease | 2 | 2017 | 86 | 0.21 | Why? |
| Blood | 2 | 2018 | 274 | 0.20 | Why? |
| Polydeoxyribonucleotides | 1 | 2021 | 118 | 0.20 | Why? |
| Drug Resistance, Multiple, Viral | 1 | 2018 | 37 | 0.19 | Why? |
| Liver Cirrhosis | 4 | 2018 | 1810 | 0.18 | Why? |
| Virus Integration | 1 | 2018 | 96 | 0.18 | Why? |
| Trans-Activators | 1 | 2018 | 170 | 0.17 | Why? |
| Gels | 1 | 2017 | 111 | 0.17 | Why? |
| Hemorrhagic Disorders | 1 | 2017 | 34 | 0.17 | Why? |
| Thymosin | 1 | 2017 | 61 | 0.16 | Why? |
| Fluorenes | 1 | 2017 | 101 | 0.16 | Why? |
| Orthomyxoviridae | 1 | 2006 | 1168 | 0.16 | Why? |
| Carbamates | 2 | 2017 | 485 | 0.16 | Why? |
| Reverse Transcriptase Inhibitors | 1 | 2018 | 309 | 0.16 | Why? |
| Macrophages | 3 | 2018 | 2784 | 0.16 | Why? |
| School Health Services | 1 | 2021 | 294 | 0.16 | Why? |
| Remission, Spontaneous | 1 | 2017 | 186 | 0.16 | Why? |
| HIV Envelope Protein gp120 | 1 | 2019 | 267 | 0.16 | Why? |
| Molecular Typing | 1 | 2017 | 280 | 0.15 | Why? |
| Sofosbuvir | 2 | 2017 | 518 | 0.15 | Why? |
| Therapies, Investigational | 1 | 2018 | 235 | 0.15 | Why? |
| Italy | 14 | 2021 | 38444 | 0.15 | Why? |
| Diagnosis, Computer-Assisted | 1 | 2020 | 436 | 0.15 | Why? |
| Latent Tuberculosis | 1 | 2019 | 324 | 0.15 | Why? |
| Hepatitis B Surface Antigens | 1 | 2017 | 305 | 0.14 | Why? |
| Benzimidazoles | 1 | 2017 | 275 | 0.14 | Why? |
| Middle Aged | 33 | 2021 | 270681 | 0.14 | Why? |
| Herpesvirus 4, Human | 1 | 2018 | 387 | 0.14 | Why? |
| Drug Substitution | 1 | 2018 | 385 | 0.14 | Why? |
| Health Surveys | 1 | 2006 | 2841 | 0.14 | Why? |
| Silver | 1 | 2017 | 327 | 0.13 | Why? |
| Hematologic Neoplasms | 2 | 2017 | 2105 | 0.13 | Why? |
| Herpesvirus 1, Human | 1 | 2017 | 286 | 0.13 | Why? |
| Plasma Exchange | 1 | 2021 | 763 | 0.13 | Why? |
| HIV Protease Inhibitors | 1 | 2017 | 434 | 0.13 | Why? |
| Virus Replication | 4 | 2018 | 14331 | 0.13 | Why? |
| CD4-Positive T-Lymphocytes | 2 | 2018 | 4545 | 0.13 | Why? |
| Liver Transplantation | 2 | 2021 | 2864 | 0.13 | Why? |
| Seasons | 1 | 2006 | 4071 | 0.12 | Why? |
| Biological Evolution | 1 | 2018 | 641 | 0.12 | Why? |
| Virus Activation | 1 | 2017 | 480 | 0.12 | Why? |
| Emigration and Immigration | 1 | 2018 | 501 | 0.12 | Why? |
| CD4 Lymphocyte Count | 4 | 2018 | 1517 | 0.12 | Why? |
| Personal Protective Equipment | 1 | 2017 | 15978 | 0.12 | Why? |
| End Stage Liver Disease | 1 | 2017 | 418 | 0.12 | Why? |
| Humans | 58 | 2021 | 930598 | 0.12 | Why? |
| Male | 33 | 2021 | 367725 | 0.12 | Why? |
| Limit of Detection | 1 | 2020 | 2698 | 0.12 | Why? |
| Receptors, Interleukin-6 | 1 | 2020 | 1383 | 0.12 | Why? |
| Female | 33 | 2021 | 380317 | 0.12 | Why? |
| Blood Safety | 1 | 2017 | 459 | 0.12 | Why? |
| Sustained Virologic Response | 3 | 2019 | 378 | 0.11 | Why? |
| Mutation | 5 | 2018 | 12376 | 0.11 | Why? |
| Aged | 21 | 2021 | 215776 | 0.11 | Why? |
| Sulfonamides | 2 | 2017 | 1294 | 0.11 | Why? |
| Plasma | 2 | 2020 | 1809 | 0.11 | Why? |
| Treatment Failure | 4 | 2018 | 2106 | 0.11 | Why? |
| Transplant Recipients | 2 | 2018 | 4982 | 0.11 | Why? |
| Cytomegalovirus Infections | 1 | 2018 | 667 | 0.11 | Why? |
| Amino Acid Substitution | 1 | 2018 | 1706 | 0.11 | Why? |
| Pneumonia, Viral | 6 | 2021 | 243684 | 0.11 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.11 | Why? |
| Alanine Transaminase | 1 | 2017 | 1329 | 0.11 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.11 | Why? |
| Genotyping Techniques | 3 | 2018 | 360 | 0.11 | Why? |
| Adult | 25 | 2021 | 244371 | 0.11 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.10 | Why? |
| Graft Rejection | 1 | 2021 | 1766 | 0.10 | Why? |
| Viral Nonstructural Proteins | 2 | 2018 | 4810 | 0.10 | Why? |
| Peptide Nucleic Acids | 1 | 2009 | 28 | 0.10 | Why? |
| Refugees | 1 | 2019 | 809 | 0.10 | Why? |
| Drug Therapy, Combination | 6 | 2018 | 7268 | 0.10 | Why? |
| Tuberculosis, Pulmonary | 1 | 2019 | 1171 | 0.09 | Why? |
| Phylogeny | 8 | 2021 | 13341 | 0.09 | Why? |
| Hepatitis B | 1 | 2017 | 888 | 0.09 | Why? |
| Software | 1 | 2020 | 2501 | 0.09 | Why? |
| Genomics | 1 | 2021 | 3118 | 0.09 | Why? |
| Liver | 3 | 2018 | 4007 | 0.09 | Why? |
| Sequence Analysis, DNA | 4 | 2018 | 2830 | 0.09 | Why? |
| Apoptosis | 1 | 2018 | 2335 | 0.09 | Why? |
| Leukocytes, Mononuclear | 1 | 2018 | 2115 | 0.09 | Why? |
| Peptide Fragments | 1 | 2019 | 2075 | 0.09 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2021 | 3607 | 0.08 | Why? |
| Blood Transfusion | 1 | 2017 | 1399 | 0.08 | Why? |
| Precision Medicine | 1 | 2017 | 1477 | 0.08 | Why? |
| Simeprevir | 2 | 2017 | 62 | 0.08 | Why? |
| Aged, 80 and over | 7 | 2021 | 88759 | 0.08 | Why? |
| Hematopoietic Stem Cell Transplantation | 2 | 2018 | 2426 | 0.08 | Why? |
| Lamivudine | 2 | 2018 | 210 | 0.08 | Why? |
| Cost of Illness | 1 | 2017 | 1903 | 0.08 | Why? |
| Ribavirin | 3 | 2018 | 1182 | 0.08 | Why? |
| Automation, Laboratory | 2 | 2020 | 536 | 0.08 | Why? |
| Cyclopropanes | 2 | 2018 | 332 | 0.07 | Why? |
| Viral Envelope Proteins | 1 | 2018 | 3539 | 0.07 | Why? |
| HIV Core Protein p24 | 2 | 2018 | 48 | 0.07 | Why? |
| Monocytes | 1 | 2017 | 2978 | 0.07 | Why? |
| Seroepidemiologic Studies | 1 | 2020 | 10017 | 0.07 | Why? |
| Community-Acquired Infections | 1 | 2017 | 2328 | 0.07 | Why? |
| Microbial Sensitivity Tests | 3 | 2018 | 2886 | 0.07 | Why? |
| Rome | 1 | 2006 | 497 | 0.07 | Why? |
| T-Lymphocytes, Cytotoxic | 2 | 2018 | 552 | 0.07 | Why? |
| Machine Learning | 1 | 2020 | 4395 | 0.07 | Why? |
| Laboratories | 1 | 2017 | 2858 | 0.07 | Why? |
| Blood Coagulation Disorders | 1 | 2017 | 2040 | 0.06 | Why? |
| Erythrocytes | 1 | 2009 | 617 | 0.06 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2020 | 13720 | 0.06 | Why? |
| Drug Carriers | 1 | 2009 | 590 | 0.06 | Why? |
| Treatment Outcome | 9 | 2020 | 51732 | 0.06 | Why? |
| Mass Screening | 2 | 2019 | 8005 | 0.06 | Why? |
| Occupational Diseases | 1 | 2017 | 2787 | 0.06 | Why? |
| Antiretroviral Therapy, Highly Active | 2 | 2018 | 952 | 0.06 | Why? |
| Adolescent | 6 | 2021 | 86841 | 0.06 | Why? |
| Antineoplastic Agents | 1 | 2017 | 3550 | 0.06 | Why? |
| Child | 5 | 2021 | 70012 | 0.06 | Why? |
| Coinfection | 2 | 2018 | 6820 | 0.05 | Why? |
| Influenza, Human | 1 | 2006 | 10779 | 0.05 | Why? |
| Protease Inhibitors | 1 | 2017 | 3630 | 0.05 | Why? |
| Young Adult | 7 | 2020 | 93724 | 0.05 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.05 | Why? |
| Africa, Eastern | 1 | 2019 | 90 | 0.05 | Why? |
| Administration, Oral | 2 | 2017 | 2340 | 0.05 | Why? |
| Prognosis | 2 | 2021 | 32490 | 0.05 | Why? |
| Prevalence | 5 | 2021 | 25773 | 0.05 | Why? |
| Immunoglobulin G | 2 | 2020 | 21571 | 0.05 | Why? |
| Asia, Western | 1 | 2019 | 271 | 0.05 | Why? |
| Antibodies, Viral | 3 | 2021 | 51949 | 0.05 | Why? |
| Alkynes | 1 | 2018 | 98 | 0.05 | Why? |
| Kinetics | 2 | 2018 | 3238 | 0.05 | Why? |
| Microfluidic Analytical Techniques | 1 | 2021 | 254 | 0.05 | Why? |
| Tuberculin Test | 1 | 2019 | 141 | 0.05 | Why? |
| Sensitivity and Specificity | 4 | 2021 | 22971 | 0.05 | Why? |
| Reproducibility of Results | 3 | 2021 | 11304 | 0.05 | Why? |
| Structural Homology, Protein | 1 | 2018 | 149 | 0.05 | Why? |
| Sequence Analysis, RNA | 2 | 2018 | 2290 | 0.05 | Why? |
| Benzoxazines | 1 | 2018 | 103 | 0.05 | Why? |
| Genome, Viral | 1 | 2021 | 13157 | 0.05 | Why? |
| Africa, Western | 1 | 2019 | 363 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.05 | Why? |
| Occupational Exposure | 1 | 2017 | 4742 | 0.04 | Why? |
| Proviruses | 1 | 2018 | 82 | 0.04 | Why? |
| Africa, Northern | 1 | 2019 | 539 | 0.04 | Why? |
| Emtricitabine | 1 | 2018 | 202 | 0.04 | Why? |
| 2-Naphthylamine | 1 | 2017 | 54 | 0.04 | Why? |
| Adaptation, Biological | 1 | 2018 | 179 | 0.04 | Why? |
| Hep G2 Cells | 1 | 2018 | 391 | 0.04 | Why? |
| Recurrence | 2 | 2018 | 3675 | 0.04 | Why? |
| Bayes Theorem | 2 | 2017 | 3237 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2021 | 9044 | 0.04 | Why? |
| Blood-Borne Pathogens | 1 | 2017 | 54 | 0.04 | Why? |
| Interferon-gamma Release Tests | 1 | 2019 | 253 | 0.04 | Why? |
| Oxazines | 1 | 2019 | 279 | 0.04 | Why? |
| Macrocyclic Compounds | 1 | 2017 | 78 | 0.04 | Why? |
| Henipavirus Infections | 1 | 2018 | 122 | 0.04 | Why? |
| Zidovudine | 1 | 2016 | 63 | 0.04 | Why? |
| HIV Envelope Protein gp41 | 1 | 2018 | 153 | 0.04 | Why? |
| Nevirapine | 1 | 2016 | 57 | 0.04 | Why? |
| Uracil | 1 | 2017 | 101 | 0.04 | Why? |
| Lactams, Macrocyclic | 1 | 2017 | 130 | 0.04 | Why? |
| Cells, Cultured | 2 | 2018 | 5835 | 0.04 | Why? |
| Furans | 1 | 2017 | 156 | 0.04 | Why? |
| Anilides | 1 | 2017 | 105 | 0.04 | Why? |
| Longevity | 1 | 2018 | 159 | 0.04 | Why? |
| Heterocyclic Compounds, 3-Ring | 1 | 2019 | 275 | 0.04 | Why? |
| Cell Cycle | 1 | 2017 | 329 | 0.04 | Why? |
| Piperazines | 1 | 2019 | 445 | 0.04 | Why? |
| Primates | 1 | 2018 | 584 | 0.04 | Why? |
| Neutralization Tests | 2 | 2021 | 6698 | 0.04 | Why? |
| Ascitic Fluid | 1 | 2017 | 169 | 0.04 | Why? |
| Infant, Newborn | 3 | 2019 | 23105 | 0.04 | Why? |
| Severity of Illness Index | 2 | 2020 | 48226 | 0.04 | Why? |
| Drugs, Investigational | 1 | 2018 | 198 | 0.04 | Why? |
| Interferons | 2 | 2018 | 2885 | 0.04 | Why? |
| Valine | 1 | 2017 | 359 | 0.04 | Why? |
| Drug Therapy | 1 | 2017 | 280 | 0.04 | Why? |
| Tenofovir | 1 | 2018 | 449 | 0.04 | Why? |
| Cross Infection | 1 | 2017 | 8675 | 0.04 | Why? |
| Proline | 1 | 2017 | 345 | 0.04 | Why? |
| Survival Analysis | 2 | 2018 | 7592 | 0.03 | Why? |
| Geography | 1 | 2021 | 1801 | 0.03 | Why? |
| Allografts | 1 | 2018 | 761 | 0.03 | Why? |
| Tuberculosis, Multidrug-Resistant | 1 | 2019 | 433 | 0.03 | Why? |
| Protein Structure, Tertiary | 1 | 2018 | 1565 | 0.03 | Why? |
| Infant | 3 | 2019 | 30274 | 0.03 | Why? |
| Retrospective Studies | 6 | 2021 | 105322 | 0.03 | Why? |
| Viral Regulatory and Accessory Proteins | 1 | 2018 | 482 | 0.03 | Why? |
| Delphi Technique | 1 | 2018 | 1257 | 0.03 | Why? |
| Oligopeptides | 1 | 2017 | 576 | 0.03 | Why? |
| Fibrosis | 1 | 2017 | 800 | 0.03 | Why? |
| Cross-Sectional Studies | 1 | 2021 | 53120 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Pyridones | 1 | 2019 | 738 | 0.03 | Why? |
| Consensus | 2 | 2019 | 6345 | 0.03 | Why? |
| Child, Preschool | 3 | 2019 | 36283 | 0.03 | Why? |
| Lopinavir | 2 | 2018 | 4308 | 0.03 | Why? |
| Antitubercular Agents | 1 | 2019 | 775 | 0.03 | Why? |
| Compassionate Use Trials | 1 | 2017 | 632 | 0.03 | Why? |
| Secondary Prevention | 1 | 2017 | 762 | 0.03 | Why? |
| Molecular Epidemiology | 1 | 2018 | 1638 | 0.03 | Why? |
| Gene Frequency | 1 | 2017 | 1210 | 0.03 | Why? |
| Ritonavir | 2 | 2017 | 4212 | 0.03 | Why? |
| Infection Control | 1 | 2021 | 23131 | 0.03 | Why? |
| Databases, Genetic | 1 | 2017 | 1127 | 0.03 | Why? |
| HIV Antibodies | 1 | 2017 | 776 | 0.03 | Why? |
| Fusion Proteins, gag-pol | 1 | 2009 | 6 | 0.03 | Why? |
| Lymph Nodes | 1 | 2017 | 1060 | 0.03 | Why? |
| Disease Progression | 2 | 2019 | 13580 | 0.02 | Why? |
| Cell Proliferation | 1 | 2017 | 1973 | 0.02 | Why? |
| Base Sequence | 1 | 2017 | 3581 | 0.02 | Why? |
| Africa | 1 | 2018 | 2986 | 0.02 | Why? |
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2009 | 95 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2018 | 4260 | 0.02 | Why? |
| Oligonucleotides, Antisense | 1 | 2009 | 111 | 0.02 | Why? |
| Immune Evasion | 1 | 2018 | 2081 | 0.02 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2017 | 2309 | 0.02 | Why? |
| Biopsy | 1 | 2017 | 2811 | 0.02 | Why? |
| Epitopes, T-Lymphocyte | 1 | 2018 | 2262 | 0.02 | Why? |
| Health Personnel | 1 | 2017 | 29646 | 0.02 | Why? |
| Reagent Kits, Diagnostic | 1 | 2017 | 2149 | 0.02 | Why? |
| Binding Sites | 1 | 2018 | 6201 | 0.02 | Why? |
| Peptides | 1 | 2018 | 2513 | 0.02 | Why? |
| Guidelines as Topic | 1 | 2019 | 2844 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Evolution, Molecular | 1 | 2019 | 3691 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2018 | 6543 | 0.02 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 3633 | 0.02 | Why? |
| Genetic Variation | 1 | 2018 | 3919 | 0.02 | Why? |
| Immunization, Passive | 1 | 2020 | 10067 | 0.02 | Why? |
| Molecular Dynamics Simulation | 1 | 2017 | 4155 | 0.02 | Why? |
| Lymphocytes | 1 | 2017 | 3056 | 0.02 | Why? |
| Antibodies, Neutralizing | 2 | 2021 | 25288 | 0.02 | Why? |
| Antigens, Viral | 1 | 2021 | 6298 | 0.02 | Why? |
| Disinfection | 1 | 2017 | 2912 | 0.02 | Why? |
| Tuberculosis | 1 | 2019 | 2895 | 0.02 | Why? |
| Molecular Docking Simulation | 1 | 2018 | 6902 | 0.02 | Why? |
| Prospective Studies | 2 | 2018 | 43301 | 0.02 | Why? |
| Radiography, Thoracic | 1 | 2019 | 5486 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2017 | 9893 | 0.01 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.01 | Why? |
| Inpatients | 1 | 2017 | 5161 | 0.01 | Why? |
| Algorithms | 1 | 2018 | 7346 | 0.01 | Why? |
| Epidemics | 1 | 2021 | 6407 | 0.01 | Why? |
| Sepsis | 1 | 2017 | 3517 | 0.01 | Why? |
| Dose-Response Relationship, Drug | 1 | 2009 | 3776 | 0.01 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2018 | 17020 | 0.01 | Why? |
| Drug Delivery Systems | 1 | 2009 | 1365 | 0.01 | Why? |
| Risk Factors | 2 | 2017 | 71621 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2017 | 10649 | 0.01 | Why? |
| Quality of Life | 1 | 2018 | 9820 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2017 | 11041 | 0.01 | Why? |
| Emergency Service, Hospital | 1 | 2021 | 14232 | 0.01 | Why? |
| Health Services Accessibility | 1 | 2019 | 10697 | 0.01 | Why? |
| Cohort Studies | 1 | 2018 | 36005 | 0.01 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.01 | Why? |
| Comorbidity | 1 | 2018 | 34796 | 0.01 | Why? |
| Risk Assessment | 1 | 2017 | 25439 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 37182 | 0.01 | Why? |
| Animals | 1 | 2018 | 78931 | 0.01 | Why? |